The DOI matches its Crossref record; 53 of the 55 references it cites were found in a registry or an index; 14 of the 23 sources its claims cite were checked for support.
Loss of electrical β-cell to δ-cell coupling underlies impaired hypoglycaemia-induced glucagon secretion in type-1 diabetes
Open accessAbstract
Diabetes mellitus involves both insufficient insulin secretion and dysregulation of glucagon secretion 1 . In healthy people, a fall in plasma glucose stimulates glucagon release and thereby increases counter-regulatory hepatic glucose production. This response is absent in many patients with type-1 diabetes (T1D) 2 , which predisposes to severe hypoglycaemia that may be fatal and accounts for up to 10% of the mortality in patients with T1D 3 . In rats with chemically induced or autoimmune diabetes, counter-regulatory glucagon secretion can be restored by SSTR antagonists 4–7 but both the underlying cellular mechanism and whether it can be extended to humans remain unestablished. Here, we show that glucagon secretion is not stimulated by low glucose in isolated human islets from donors with T1D, a defect recapitulated in non-obese diabetic mice with T1D. This occurs because of hypersecretion of somatostatin, leading to aberrant paracrine inhibition of glucagon secretion. Normally, K ATP channel-dependent hyperpolarization of β-cells at low glucose extends into the δ-cells through gap junctions, culminating in suppression of action potential firing and inhibition of somatostatin secretion. This ‘electric brake’ is lost following autoimmune destruction of the β-cells, resulting in impaired counter-regulation. This scenario accounts for the clinical observation that residual β-cell function correlates with reduced hypoglycaemia risk 8 .
Overview
CoChat Summary
TL;DR
In type-1 diabetes, low glucose fails to stimulate glucagon secretion because β-cell destruction removes an electrical “brake” on δ-cells, causing somatostatin hypersecretion that paracrine-inhibits α-cells. Restoring this brake pharmacologically or genetically restores hypoglycaemia-induced glucagon secretion in mouse and human islets.
Key findings
- In isolated human islets, lowering glucose from 6 mM to 1 mM stimulated glucagon secretion by 147 ± 45% in non-diabetic donors but only 7 ± 9% in T1D donors; T1D islets still responded to amino acids (+68 ± 2%) or the somatostatin receptor antagonist CYN154806 (+68 ± 15%).
- In NOD mice, low glucose stimulated glucagon secretion by 348 ± 100% in non-diabetic mice versus 34 ± 15% in T1D mice, while arginine responsiveness was preserved; CYN154806 increased glucagon secretion from ~300% in young non-diabetic islets to >750% in adult T1D islets and partially restored hypoglycaemia-induced plasma glucagon in vivo.
- The mechanism is loss of β-cell-to-δ-cell electrical coupling: at low glucose, β-cell KATP-dependent hyperpolarization spreads through gap junctions to suppress δ-cell action potentials and somatostatin release. Gap-junction blockers (MFQ, CBX) or cytokine treatment stimulated somatostatin and inhibited glucagon; optogenetic β-cell hyperpolarization hyperpolarized δ-cells and inhibited somatostatin; β-V59M KATP mice showed δ-cells refractory to glucose.
- In silico modelling indicated >90% of δ-cells remain in contact with at least one β-cell until >75% of β-cells are deleted, consistent with residual β-cell function protecting against hypoglycaemia.
Methods
- Used NOD mice with and without T1D, isolated mouse and human islets, perfused mouse pancreas, and in vivo insulin-induced hypoglycaemia with plasma glucagon measurements.
- Measured hormone secretion by ELISA/radioimmunoassay, performed perforated-patch electrophysiology in intact islets, optogenetic NpHR activation in β-cells, cytokine-cocktail treatment, qPCR/single-cell RNA sequencing, and mathematical modelling of β-cell–δ-cell contacts.
- Statistical comparisons used one- or two-tailed t-tests, one-way ANOVA with post hoc tests, and repeated-measures ANOVA where appropriate; data are mean ± s.e.m.
Limitations
- The paper states that some observations on prevention of β-cell destruction in NOD mice have not translated to humans, though it focuses on α-cell and δ-cell function.
- The paper notes that optogenetic inhibition of insulin secretion was surprisingly weak, possibly due to poor light penetration into deeper islet layers, and that CBX can inhibit voltage-gated Ca²⁺ channels, which may contribute to its weaker effects.
- Evident from the text: human T1D islet data come from a limited number of donors (6 T1D donors overall, with some experiments using 4 donors), and most NOD mouse experiments used female mice because they develop T1D earlier.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






![Extended Data Fig. 3 Impaired counter-regulation in NOD mice with T1D and correction by CYN154806. a-b, Changes in plasma glucose (a) and glucagon (b) in the absence (o; n = 8) and presence (•; n = 6) of CYN154806 in adult ND NOD mice. Insulin (0.75U/kg body weight) was injected at t = 0 (black arrow in a) and CYN154806 (0.5 mg/kg body weight) or vehicle was injected at t = −15 min (red arrow in a). c-d, As in (a-b) but using age-matched T1D NOD mice (n = 8 without and 5 with CYN154806). *p < 0.05 vs without CYN, two-sided Student’s t-test. e, Changes in plasma glucose (black) and glucagon (red) in T1D NOD mice (n = 3). Insulin (0.75U/kg body weight) was injected at t = 0 and 30 min (arrows). f, Plasma glucagon during hypoglycaemia induced by two consecutive insulin injections (0.75U/kg body weight) in T1D NOD mice (to lower plasma glucose to levels similar to those observed in ND mice). Data are expressed as the area under the curve (AUC) above basal (t = 30 min) during the 45 min following the second insulin injection (n = 3). For comparison, the responses in ND NOD mice are shown (mean value [dashed circle] ± S.E.M. [dashed lines], data taken from Fig. 1j); *p = 0.029 vs ND NOD mice, two-sided Student’s t-test. g-h, Relationship of plasma glucagon and glucose in ND (g) and T1D (h) NOD mice during insulin-induced hypoglycaemia in the absence (black) and presence (red) of CYN154806. Dashed lines mark the linear regression fittings of the data. Values of slopes (pM/mM) are given as well as the p values of the respective relationships obtained in the absence (vehicle) or presence of CYN154806. Statistical significance was evaluated using t-test. i, Glycogen content in livers from adult ND (n = 24) and T1D NOD (n = 9) mice. *p = 0.038 vs ND, two-sided Student’s t-test. In dot plots, rectangles and error bars behind data points represent mean values ± S.E.M. Source data](https://figures.cochat.ai/paper-figures/5b03650e7a22463e9f427260fd8f97d6/loss-of-electrical-cell-to-cell-coupling-underlies-impaired-hypoglycaemia-figure-7.jpg)



![Extended Data Fig. 7 Electrical coupling and [Ca2+]i in δ-cells. a-b, [Ca2+]i oscillations recorded in single δ-cells in intact islets from Sst-GCaMP6f mice under control conditions (a) and after pretreatment (1 h) with 1 μM mefloquine (b). Experiments were concluded by increasing extracellular K+ to 70 mM to depolarise the δ-cells. Islets were pretreated with ryanodine (50 μM for 1 h) to minimise the contribution of intracellular Ca2+ release. (a, b) are each representative of 139–143 cells in 6 islets from 2 mice. c, Fraction of spontaneously active δ-cells within intact islets in the absence and presence of 1 µM mefloquine as indicated. *p = 0.019 vs no mefloquine (n = 6 islets obtained from 2 mice), two-sided Student’s t-test. d, Frequency of δ-cell [Ca2+]i oscillations in the absence and presence of 1 μM mefloquine as indicated. *p = 0.042 (139 δ-cells in 6 islets from 2 mice without mefloquine and 143 δ-cells in 6 islets from 2 mice with mefloquine), two-sided Student’s t-test. e, Violin plots of δ-cell [Ca2+]i oscillations in intact islets (240 δ-cells from 2 mice) and in dispersed islet cell preparations (380 δ-cells from 2 mice). *p = 0.038 vs intact islets, two-sided Student’s t-test. In dot plots, rectangles and error bars behind data points represent mean values ± S.E.M. Note stimulation of spontaneous [Ca2+]i oscillations in the presence of the gap junction blocker mefloquine and that the depolarization-induced (high K+-induced) [Ca2+]i increase was not affected by the inhibitor. Source data](https://figures.cochat.ai/paper-figures/2f681f8e33264cc88974369b14b3bdc5/loss-of-electrical-cell-to-cell-coupling-underlies-impaired-hypoglycaemia-figure-11.jpg)



Verification
Claims the paper makes
8 Valid · 3 Not valid · 3 Not checked · 32 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In rats with chemically induced or autoimmune diabetes, counter-regulatory glucagon secretion can be restored by SSTR antagonists4–7”
§ Loss of electrical β-cell to δ-cell coupling underlies impaired hypoglycaemia-induced glucagon secretion in type-1 diabetes > Abstract
What the sources say
- Partly supportedcites [4] Yue, J. T. et al. Amelioration of hypoglycemia via somatostatin receptor type 2 antagonism in recurrently hypoglycemic diabetic rats. Diabetes 62, 2215–2222 (2013). sourceExperimental — accuracy not yet measured
The Abstract reports that SSTR2 antagonism improved the glucagon response to hypoglycemia in streptozotocin-diabetic rats, and Research Design and Methods identifies streptozotocin injection as the means of inducing diabetes. The paper does not report an autoimmune-diabetes rat group. Its Discussion also says the response after recurrent hypoglycemia was not fully restored, so “restored” overstates this study’s finding. (LLM, conf=0.88)
- Supportedcites [5] Yue, J. T. et al. Somatostatin receptor type 2 antagonism improves glucagon and corticosterone counterregulatory responses to hypoglycemia in streptozotocin-induced diabetic rats. Diabetes 61, 197–207 (2012). source
The Abstract reports that an SSTR2 antagonist fully restored the attenuated glucagon response to hypoglycemia in streptozotocin-induced diabetic rats. This source supports the chemically induced diabetes part of the multiply cited sentence; it does not need to establish the autoimmune-diabetes part. (LLM, conf=0.92)
- Supportedcites [6] Karimian, N. et al. Somatostatin receptor type 2 antagonism improves glucagon counterregulation in biobreeding diabetic rats. Diabetes 62, 2968–2977 (2013). source
The Discussion reports that SSTR2 antagonism restored glucagon counterregulation during insulin-induced hypoglycemia in both chemically induced (STZ) diabetic rats and autoimmune diabetic BBDP rats. The chemically induced result is described as a previous study, while the autoimmune result is from this paper. (LLM, conf=0.93)
- Misattributedcites [7] Hoffman, E. G. et al. Somatostatin receptor antagonism reverses glucagon counterregulatory failure in recurrently hypoglycemic male rats. Endocrinology 162, bqab189 (2021). sourceExperimental — accuracy not yet measured
Our copy of Hoffman et al. (2021) is explicitly a NONDIABETIC study: the Introduction (p. 1, 'In this study, we used a nondiabetic rat model...') and the Discussion summary ('restored glucagon counterregulation ... in recurrently hypoglycemic, nondiabetic rats') show the paper's own experiment used healthy male Sprague-Dawley rats, with no streptozotocin or biobreeding diabetes. The diabetic-model point in the claim appears in this paper only as credited background: the Introduction states 'In preclinical trials, SSTR2a was shown to restore glucagon counterregulation ... in rodent models of streptozotocin and biobreeding T1D (25,26,27)', and the Discussion repeats 'The rescue of glucagon counterregulation by SSTR2a in various diabetic rodent models during acute (25,26) and recurrent (27) hypoglycemia'. The References section names those works: Yue et al., Diabetes 2012 (streptozotocin-induced = chemically induced) and Karimian et al., Diabetes 2013 (biobreeding = autoimmune), plus Yue et al., Diabetes 2013 (recurrently hypoglycemic diabetic rats) — so the claim belongs to those papers, not to this one. (LLM, conf=0.80) It matches “Somatostatin receptor type 2 antagonism improves glucagon and corticosterone counterregulatory responses to hypoglycemia in streptozotocin-induced diabetic rats” (2012) instead.
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Pancreatic β-cells and δ-cells are electrically coupled14.”
§ Loss of electrical β-cell to δ-cell coupling underlies impaired hypoglycaemia-induced glucagon secretion in type-1 diabetes > Main
What the sources say
- Supportedcites [14] Briant, L. J. B. et al. δ-Cells and β-cells are electrically coupled and regulate α-cell activity via somatostatin. J. Physiol. 596, 197–215 (2018). source
The Discussion section, “Functional GJ connections between β- and δ-cells,” states that the authors demonstrate functional gap-junction connections between the two cell types. It reports that δ-cell action potentials could be triggered by optogenetic activation of β-cells, supporting the claim of electrical coupling. (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Urocortin-3, co-released with insulin from β-cells, is a paracrine stimulator of somatostatin secretion13.”
§ Loss of electrical β-cell to δ-cell coupling underlies impaired hypoglycaemia-induced glucagon secretion in type-1 diabetes > Main
What the sources say
- Supportedcites [13] van der Meulen, T. et al. Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion. Nat. Med. 21, 769–776 (2015). source
The Introduction states that Ucn3 is co-secreted with insulin and promotes somatostatin secretion from delta cells. The Discussion likewise says Ucn3 is released with insulin from beta-cell granules and promotes somatostatin release through a negative-feedback loop. (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“This scenario accounts for the clinical observation that residual β-cell function correlates with reduced hypoglycaemia risk8.”
§ Loss of electrical β-cell to δ-cell coupling underlies impaired hypoglycaemia-induced glucagon secretion in type-1 diabetes > Abstract
What the sources say
- Supportedcites [8] Gubitosi-Klug, R. A. et al. Residual beta cell function in long-term type 1 diabetes associates with reduced incidence of hypoglycemia. J. Clin. Invest. 131, e143011 (2021). source
The source paper's title and Abstract (p. 1) state that the proportion of subjects with a history of severe hypoglycemia was lower with high (27%) and intermediate (48%) residual C-peptide concentrations than with low (74%) and none (70%), P for trend = 0.0001. The Results section quantifies it as peak C-peptide >0.03 nmol/L associating with a ~50% reduced proportion of participants with frequent severe hypoglycemia, calling residual C-peptide secretion a long-term protective factor, and the Discussion (summary) reiterates the salutary effect of residual β cell function in reducing long-term severe hypoglycemia risk. The citing sentence attributes only this association, which our copy states directly. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“This remained >90% until >75% of the β-cells had been deleted (Fig. 4j).”
§ Loss of electrical β-cell to δ-cell coupling underlies impaired hypoglycaemia-induced glucagon secretion in type-1 diabetes > Main
What the sources say
- Could not verifycites [40] Hoang, D. T. et al. A conserved rule for pancreatic islet organization. PLoS ONE 9, e110384 (2014). sourceExperimental — accuracy not yet measured
The Results section on spatial organization of δ cells examines human islet structure and inferred cell attractions, but does not report how many δ-cells remain in contact with a β-cell after β-cell deletion. Searches for 75% deletion and β-cell loss found no such simulation or >90% contact threshold in our copy. (LLM, conf=0.75)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
13 more claims · 1 with their cited sources checked
Create a free account to see all 46 claims and to verify the 2 references still open.
- It may state two separate claims as one. 22
- Probably not a substantial claim. 7
- The quote only partly states this claim. 2
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Loss of electrical β-cell to δ-cell coupling underlies impaired hypoglycaemia-induced glucagon secretion in type-1 diabetes > Main
“c, Amplitudes of light-induced currents (ΔI) in δ-cells ±200 μM CBX.”
§ Loss of electrical β-cell to δ-cell coupling underlies impaired hypoglycaemia-induced glucagon secretion in type-1 diabetes > Methods > Electrophysiological recordings
“In the CBX experiments, islets were pre-incubated in 100 μM CBX for 1 h and the electrophysiological measurements were performed in the continued presence of CBX.”
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Loss of electrical β-cell to δ-cell coupling underlies impaired hypoglycaemia-induced glucagon secretion in type-1 diabetes > Main
“They raise the interesting possibility that the protective effect of residual β-cell function is mediated by β-cell to δ-cell electrical coupling and β-cell hyperpolarization rather than secreted factors, leading to stimulation of somatostatin secretion and suppression of glucagon secretion.”
§ Loss of electrical β-cell to δ-cell coupling underlies impaired hypoglycaemia-induced glucagon secretion in type-1 diabetes > Main
“At low glucose, KATP channel activity is high in β-cells, resulting in membrane repolarization that spreads into δ-cells through gap junctions and leads to suppression of action potential firing and somatostatin release (see schematic in Supplementary Fig. 2a).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Loss of electrical β-cell to δ-cell coupling underlies impaired hypoglycaemia-induced glucagon secretion in type-1 diabetes > Main
“As a result, there was a negative correlation between somatostatin and glucagon secretion (Fig. 2c).”
§ Loss of electrical β-cell to δ-cell coupling underlies impaired hypoglycaemia-induced glucagon secretion in type-1 diabetes > Main
“c, Relationship between somatostatin secretion and glucagon secretion. Line: linear regression fitting of the data (r = 0.669; P < 0.0001).”
Citations
Cites
A new mathematical model for relative quantification in real-time RT-PCR
Pfaffl, M. W. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.9.e45 · Cited by 34,610 · cited 1×
“Relative quantification was assessed using the ΔΔCT method 52 .”
A toolbox of Cre-dependent optogenetic transgenic mice for light-induced activation and silencing
Madisen, L., Mao, T., Koch, H., Zhuo, J.-M., Berenyi, A., Fujisawa, S., Hsu, Y.-W. A., Garcia, A. J., Gu, X., Zanella, S., et al. (2012) · Nature Neuroscience · doi:10.1038/nn.3078 · Cited by 1,398
Gerich, J. E., Langlois, M., Noacco, C., Karam, J. H., & Forsham, P. H. (1973) · Science · doi:10.1126/science.182.4108.171 · Cited by 688 · cited 2×
“The failure of insulin-induced hypoglycaemia to increase plasma glucagon in T1D was first documented 50 years ago 2 .”
Adult insulin- and glucagon-producing cells differentiate from two independent cell lineages
Herrera, P. L. (2000) · Development · doi:10.1242/dev.127.11.2317 · Cited by 672
The NOD mouse model of type 1 diabetes: As good as it gets?
Atkinson, M. A., & Leiter, E. H. (1999) · Nature Medicine · doi:10.1038/9442 · Cited by 588 · cited 1×
“We used non-obese diabetic (NOD) mice, a widely used polygenic mouse model of human T1D 9,10 , to explore why hypoglycaemia-induced glucagon secretion becomes impaired in diabetes.”
Cellular composition of the human diabetic pancreas
Rahier, J., Goebbels, R. M., & Henquin, J. C. (1983) · Diabetologia · doi:10.1007/bf00251826 · Cited by 395 · cited 1×
“2a–c), in agreement with human histological data 11 .”
Ravier, M. A., Güldenagel, M., Charollais, A., Gjinovci, A., Caille, D., Söhl, G., Wollheim, C. B., Willecke, K., Henquin, J.-C., & Meda, P. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1798 · Cited by 360
DiGruccio, M. R., Mawla, A. M., Donaldson, C. J., Noguchi, G. M., Vaughan, J., Cowing-Zitron, C., van der Meulen, T., & Huising, M. O. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.04.007 · Cited by 353 · cited 2×
“5c), which encodes the gap junction protein connexin-36, expressed in both β-cells and δ-cells 15,16 .”
Potent block of Cx36 and Cx50 gap junction channels by mefloquine
Cruikshank, S. J., Hopperstad, M., Younger, M., Connors, B. W., Spray, D. C., & Srinivas, M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402044101 · Cited by 350 · cited 12×
“** P < 0.01; *** P < 0.001; **** P < 0.0001 vs 1 mM glucose ( n = 6 using four mice). m , n , Somatostatin ( m ) and glucagon ( n ) secretion at 1 mM glucose in islets from T1D NOD mice with or without MFQ as indicated ( n = 5 using five T1D NOD mice; blood glucose >33 mM).”
InfluentialThe importance of the Non Obese Diabetic (NOD) mouse model in autoimmune diabetes
Pearson, J. A., Wong, F. S., & Wen, L. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2015.08.019 · Cited by 298 · cited 1×
“We acknowledge that some observations on the prevention of β-cell destruction in NOD mice have not been possible to translate to humans 46,47 , but here we focus on the impact of T1D on α-cell and δ-cell function, of which much less is known.”
Research works printed but not linked: 1
- Kachapati, K., Adams, D., Bednar, K. & Ridgway, W. M. in Animal Models in Diabetes Research (eds Joost, H.-G. et al.) 3–16 (Humana Press, 2012). · DOI · Paper page
Cited by
Inflammatory signaling pathways in pancreatic β-cell: New insights into type 2 diabetes pathogenesis
Chen, J., Fei, S., Chan, L., Gan, X., Shao, B., Jiang, H., Li, S., Kuang, P., Liu, X., & Yang, S. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107776 · Cited by 58
Heterogeneous endocrine cell composition defines human islet functional phenotypes
Evans-Molina, C., Pettway, Y. D., Saunders, D. C., Sharp, S. A., Bate, T. S. R., Sun, H., Durai, H., Mei, S., Coldren, A., Davis, C., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-70689-5 · Cited by 5
Henriksen, K., Rufer, C., Title, A. C., Jawurek, S., Hartmann, B., Holst, J. J., Knop, F. K., Yesildag, B., & Størling, J. (2025) · Diabetologia · doi:10.1007/s00125-025-06425-3 · Cited by 8
Self-citationdos Santos, T., Dai, X.-Q., Jones, R. C., Spigelman, A. F., Mummey, H. M., Ewald, J., Ellis, C. E., Lyon, J. G., Smith, N. P., Bautista, A., et al. (2025) · Yearbook of pediatric endocrinology · doi:10.1172/jci195267 · Cited by 18
“And islets from 6 donors with T1D (3 included in the present study), showed glucagon secretion that was unresponsive to glucose but increased with amino acids (70).”
Chen, Y., Chen, B. S., Zhou, X., et al. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.5c19789 · Cited by 7
Metadata
- Authors
- Hill, T. G., Gao, R., Benrick, A., Kothegala, L., Rorsman, N., Santos, C., Acreman, S., Briant, L. J., Dou, H., Gandasi, N. R., Guida, C., Haythorne, E., Wallace, M., Knudsen, J. G., Miranda, C., Tolö, J., Clark, A., Davison, L., Størling, J., Tarasov, A., Ashcroft, F. M., Rorsman, P., & Zhang, Q.
- Affiliations
- University of Oxford (GB)
- University of Gothenburg (SE)
- Indian Institute of Science Bangalore (IN)
- Royal Veterinary College (GB)
- University of Copenhagen (DK)
- Steno Diabetes Center Copenhagen (DK)
- University of Ulster (GB)
- Corresponding author
- Rorsman, Patrik
- Zhang, Quan
- ORCID
- Gao, Rui
- Benrick, Anna
- Kothegala, Lakshmi
- Santos, Cristiano
- Acreman, Samuel
- Briant, Linford J.
- Dou, Haiqiang
- Gandasi, Nikhil R.
- Guida, Claudia
- Haythorne, Elizabeth
- Wallace, Marsha
- Knudsen, Jakob G.
- Miranda, Caroline
- Tolö, Johan
- Davison, Lucy
- Størling, Joachim
- Tarasov, Andrei
- Ashcroft, Frances M.
- Rorsman, Patrik
- Zhang, Quan
- Venue
- Nature Metabolism
- Published
- 2024-09-23
- Volume
- 6
- Issue
- 11
- Pages
- 2070-2081
- ISSN
- 2522-5812 (ISSN-L)
- PMC
- PMC11599053
- OpenAlex
- W4402750187
- Cited by
- 37
- References
- 55
- Citations by year
- 2026: 21 · 2025: 15 · 2024: 1
- FWCI
- 10.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Metabolism (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Oxford University Research Archive (ORA) (University of Oxford) (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- Ulster University Research Portal (Ulster University) (publishedVersion, cc-by)
- NOT FOUND REPOSITORY (Indian Institute of Science Bangalore) (acceptedVersion)
- Funders
- Diabetes UK (14/0005128)
- Wellcome Trust (201325/Z/16/Z)
- RCUK | Medical Research Council (MR/VO11979/1, MR/T002107/1)
- Leona M. and Harry B. Helmsley Charitable Trust (G-1912-03553, G-2305-06047)
- Vetenskapsrådet (2013-7107)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 1 diabetes, glucagon secretion, hypoglycemia, somatostatin, gap junctions, ATP-sensitive potassium channels, counterregulation, islets, NOD mice, autoimmune beta-cell destruction
- MeSH terms
- Animals, Diabetes Mellitus, Type 1, Female, Glucagon, Glucose, Humans, Hypoglycemia, Male, Somatostatin, Mice, Inbred NOD, Somatostatin-Secreting Cells, Insulin-Secreting Cells, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Loss of electrical β-cell to δ-cell coupling underlies impaired hypoglycaemia-induced glucagon secretion in type-1 diabetes. https://app.cochat.ai/papers/10.1038/s42255-024-01139-z
- The paper
- Hill, T. G., Gao, R., Benrick, A., Kothegala, L., Rorsman, N., Santos, C., Acreman, S., Briant, L. J., Dou, H., Gandasi, N. R., Guida, C., Haythorne, E., Wallace, M., Knudsen, J. G., Miranda, C., Tolö, J., Clark, A., Davison, L., Størling, J., . . . Zhang, Q. (2024). Loss of electrical β-cell to δ-cell coupling underlies impaired hypoglycaemia-induced glucagon secretion in type-1 diabetes. Nature Metabolism. https://doi.org/10.1038/s42255-024-01139-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.